Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
Beximco Pharmaceuticals Limited (BXP) - Total Assets
Latest total assets as of December 2024: GBX73.80 Billion GBX
Based on the latest financial reports, Beximco Pharmaceuticals Limited (BXP) holds total assets worth GBX73.80 Billion GBX as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beximco Pharmaceuticals Limited - Total Assets Trend (2005–2024)
This chart illustrates how Beximco Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beximco Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Beximco Pharmaceuticals Limited's total assets of GBX73.80 Billion consist of 30.0% current assets and 70.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 1.2% |
| Accounts Receivable | GBX4.02 Billion | 5.8% |
| Inventory | GBX13.01 Billion | 18.8% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX4.72 Billion | 6.8% |
| Goodwill | GBX674.57 Million | 1.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Beximco Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beximco Pharmaceuticals Limited's current assets represent 30.0% of total assets in 2024, a decrease from 31.9% in 2005.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 3.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 18.8% of total assets.
Beximco Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Beximco Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Beximco Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Beximco Pharmaceuticals Limited generates 0.64x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Beximco Pharmaceuticals Limited generates $8.41 in net profit.
Beximco Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 1.63 | 1.06 |
| Quick Ratio | 0.83 | 0.64 | 0.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX13.09 Billion | GBX 8.54 Billion | GBX 749.39 Million |
Beximco Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Beximco Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | GBX69.34 Billion |
| Market Capitalization | $31.61K USD |
Valuation Analysis
Below Book Valuation: The market values Beximco Pharmaceuticals Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beximco Pharmaceuticals Limited's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beximco Pharmaceuticals Limited (2005–2024)
The table below shows the annual total assets of Beximco Pharmaceuticals Limited from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | GBX69.34 Billion | +0.27% |
| 2023-06-30 | GBX69.16 Billion | +4.55% |
| 2022-06-30 | GBX66.15 Billion | +26.61% |
| 2021-06-30 | GBX52.25 Billion | +4.24% |
| 2020-06-30 | GBX50.12 Billion | +1.84% |
| 2019-06-30 | GBX49.21 Billion | +12.52% |
| 2018-06-30 | GBX43.74 Billion | +28.33% |
| 2017-06-30 | GBX34.08 Billion | +9.42% |
| 2016-06-30 | GBX31.15 Billion | +1.02% |
| 2015-12-31 | GBX30.84 Billion | +6.33% |
| 2014-12-31 | GBX29.00 Billion | +5.57% |
| 2013-12-31 | GBX27.47 Billion | +11.72% |
| 2012-12-31 | GBX24.59 Billion | +6.76% |
| 2011-12-31 | GBX23.03 Billion | +7.77% |
| 2010-12-31 | GBX21.37 Billion | +7.44% |
| 2009-12-31 | GBX19.89 Billion | +34.23% |
| 2008-12-31 | GBX14.82 Billion | +23.98% |
| 2007-12-31 | GBX11.95 Billion | +0.34% |
| 2006-12-31 | GBX11.91 Billion | +8.84% |
| 2005-12-31 | GBX10.95 Billion | -- |